Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-88549968 in CALR-mutated Myeloproliferative Neoplasms
NCT06150157Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 1, open-label, single-arm trial of JNJ-88549968 in essential thrombocythemia (ET) and myelofibrosis (MF), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 35 days, Adverse Events at 2 years and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
JNJ-88549968
03
Conditions
essential thrombocythemia (ET)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06150157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06150157.